Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK dismisses critical antidepressant study

GSK dismisses critical antidepressant study

28th February 2008

GlaxoSmithKline (GSK) has rejected the findings of a new study which suggests that antidepressants have limited clinical benefit to most patients.

Responding to the research, which was published in the Public Library of Science Medicine, the company stated that it believed the authors’ interpretation to be “incorrect” and “at odds” with the benefits observed in patients by other clinical studies.

GSK added that regulatory bodies across the globe had conducted extensive reviews of the published and unpublished data for licensed antidepressants and had concluded that the medicines provided benefits to patients.

The pharmaceutical giant went on to criticise how the study was reported, suggesting that it had “caused unnecessary alarm and concern for patients”.

“Antidepressant medicines remain an important option, in addition to counselling and lifestyle changes, for patients suffering from depression.”

It continued to indicate that the study only examined a small subset of total data available for antidepressants, contrary to reports.

Highlighting paroxetine, GSK outlined that the research only considers data from 16 trials out of a total database of more than 170 trials involving over 14,000 patients.

Also this week, GSK and Theravance have announced the expansion of their Horizon programme which seeks to develop a next-generation combination treatment for patients with chronic obstructive pulmonary disorder.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.